The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Eli Lilly and Co

NYSE: LLY
Last

(U.S.) $79.80

Today's change-2.55 -3.10%
Updated September 1 4:03 PM EDT. Delayed by at least 15 minutes.
 

Eli Lilly and Co

NYSE: LLY
Last

(U.S.) $79.80

Today's change-2.55 -3.10%
Updated September 1 4:03 PM EDT. Delayed by at least 15 minutes.

Eli Lilly and Co down (U.S.)$2.55

Eli Lilly and Co closed sharply lower Tuesday, dropping (U.S.)$2.55 or 3.10% to (U.S.)$79.80. Over the last five days, shares have gained 1.97% and 15.67% year to date. Shares have outperformed the S&P 500 by 30.02% during the last year.

Key company metrics

  • Open(U.S.) $80.25
  • Previous close(U.S.) $82.35
  • High(U.S.) $81.25
  • Low(U.S.) $79.40
  • Bid / Ask-- / --
  • YTD % change+15.67%
  • Volume4,300,485
  • Average volume (10-day)6,141,722
  • Average volume (1-month)4,552,157
  • Average volume (3-month)5,639,177
  • 52-week range(U.S.) $60.58 to (U.S.) $90.18
  • Beta0.28
  • Trailing P/E41.42×
  • P/E 1 year forward25.10×
  • Forward PEG2.46×
  • Indicated annual dividend(U.S.) $2.00
  • Dividend yield2.51%
  • Trailing EPS(U.S.) $1.93
Updated September 1 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+10.50%

Based on its net profit margin of 10.50%, Eli Lilly and Co is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.72%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue4,9794,6455,1214,876
Total other revenue--------
Total revenue4,9794,6455,1214,876
Gross profit3,7603,4523,8683,609
Total cost of revenue1,2181,1931,2531,267
Total operating expense4,3424,1204,7454,314
Selling / general / administrative1,6351,5241,8001,672
Research & development1,1701,0391,1861,243
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)319364506131
Other operating expenses, total--------
Operating income636525376562
Interest income (expense), net non-operating-50-54-49-48
Gain (loss) on sale of assets--------
Other--------
Income before tax680618514656
Income after tax601530429501
Income tax, total798885155
Net income601530429501
Total adjustments to net income--------
Net income before extra. items601530429501
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items601530429501
Inc. avail. to common incl. extra. items601530429501
Diluted net income601530429501
Dilution adjustment--------
Diluted weighted average shares1,0661,0671,0701,074
Diluted EPS excluding extraordinary itemsvalue per share0.560.500.400.47
Dividends per sharevalue per share0.500.500.500.49
Diluted normalized EPSvalue per share0.840.820.810.58